A clinical trial with a mAb against CD47 (Hu5F9-G4) in combination with anti-PD-L1 (Avelumab) is currently underway for ovarian cancer patients who progressed within 6 months of prior platinum-based chemotherapy (NCT03558139) [224,407]. Here, CD274 is linked to ovarian cancer.